The landscape of the disease treatment is undergoing a significant change with the emergence of rapidly melting GLP-1 therapies. These innovative formulations, designed to rapidly dissolve under the tongue, offer the promise for faster absorption and a minimized need for regular injections. This strategy could optimize patient adherence and potenti

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturin